181 related articles for article (PubMed ID: 26122869)
1. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
Cervantes F; Alvarez-Larrán A; Domingo A; Arellano-Rodrigo E; Montserrat E
Br J Haematol; 2005 Jun; 129(6):771-5. PubMed ID: 15953003
[TBL] [Abstract][Full Text] [Related]
3. Danazol treatment of idiopathic myelofibrosis with severe anemia.
Cervantes F; Hernández-Boluda JC; Alvarez A; Nadal E; Montserrat E
Haematologica; 2000 Jun; 85(6):595-9. PubMed ID: 10870115
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
[TBL] [Abstract][Full Text] [Related]
6. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
Lévy V; Bourgarit A; Delmer A; Legrand O; Baudard M; Rio B; Zittoun R
Am J Hematol; 1996 Dec; 53(4):239-41. PubMed ID: 8948661
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
Hasselbalch HC; Clausen NT; Jensen BA
Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Martínez-Trillos A; Gaya A; Maffioli M; Arellano-Rodrigo E; Calvo X; Díaz-Beyá M; Cervantes F
Ann Hematol; 2010 Dec; 89(12):1233-7. PubMed ID: 20567824
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of prednisone treatment for the anemia of myelofibrosis.
Hernández-Boluda JC; Martínez-Trillos A; García-Gutiérrez V; Ferrer-Marín F; Xicoy B; Alvarez-Larrán A; Kerguelen A; Barba P; Gómez M; Herrera JC; Correa JG; Cervantes F
Leuk Lymphoma; 2016; 57(1):120-4. PubMed ID: 25944376
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Qu S; Xu Z; Qin T; Li B; Pan L; Chen J; Yan X; Wu J; Zhang Y; Zhang P; Gale RP; Xiao Z
Hematol Oncol; 2022 Oct; 40(4):787-795. PubMed ID: 35609279
[TBL] [Abstract][Full Text] [Related]
13. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan.
Shimoda K; Shide K; Kamezaki K; Okamura T; Harada N; Kinukawa N; Ohyashiki K; Niho Y; Mizoguchi H; Omine M; Ozawa K; Haradaa M
Int J Hematol; 2007 May; 85(4):338-43. PubMed ID: 17483079
[TBL] [Abstract][Full Text] [Related]
14. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E
Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
Gowin K; Kosiorek H; Dueck A; Mascarenhas J; Hoffman R; Reeder C; Camoriano J; Tibes R; Gano K; Palmer J; Mesa R
Leuk Res; 2017 Sep; 60():31-35. PubMed ID: 28646676
[TBL] [Abstract][Full Text] [Related]
17. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol.
Schiavotto C; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):29-34. PubMed ID: 8039755
[TBL] [Abstract][Full Text] [Related]
18. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
